Changes in plasma lipids predict pravastatin efficacy in secondary prevention.
Jayawardana KS, Mundra PA, Giles C, Barlow CK, Nestel PJ, Barnes EH, Kirby A, Thompson P, Sullivan DR, Alshehry ZH, Mellett NA, Huynh K, McConville MJ, Zoungas S, Hillis GS, Chalmers J, Woodward M, Marschner IC, Wong G, Kingwell BA, Simes J, Tonkin AM, Meikle PJ; LIPID Study Investigators.
Jayawardana KS, et al. Among authors: giles c.
JCI Insight. 2019 Jul 11;4(13):e128438. doi: 10.1172/jci.insight.128438. eCollection 2019 Jul 11.
JCI Insight. 2019.
PMID: 31292301
Free PMC article.
Clinical Trial.